ERBB2 and breast cancer: Secondly, although intrathecal trastuzumab was associated with better OS, none of the patients with HER2-positive breast cancer with LM received intravenous trastuzumab, and continued systemic anti-HER2 treatment after CNS metastases may be associated with improved survival [2].